Abstract
PurposeTo evaluate the effect of spironolactone, a mineralocorticoid receptor antagonist, for naïve and nonresolving central serous chorioretinopathy.MethodsA retrospective chart review was conducted of all central serous chorioretinopathy patients at one center treated with spironolactone (50 mg once a day) or observation. Thirty eyes of 30 patients with central serous chorioretinopathy and persistent subretinal fluid (SRF) for at least 8 weeks were enrolled. Patients were followed at monthly intervals with examination and optical coherence tomography. The primary outcome measure was the changes in SRF thickness from baseline to the apex of the serous retinal detachment. Secondary outcome included the best‐corrected visual acuity (BCVA).ResultsThe mean duration of central serous chorioretinopathy before enrollment in study eyes was 11.13 ± 2.40 weeks. Spironolactone demonstrated statistically significant visual acuity improvement (0.12 ± 0.09) and SRF reduction (273.07 ± 71.16 μm) at 3 months compared to baseline (0.25 ± 0.17, p = 0.003; 432.57 ± 108.99 μm, p = 0.001, respectively). Eight of the 14 patients with spironolactone had complete resolution of SRF at 3 months, compared to six of the 16 patients under observation (p = 0.377). Data analysis showed a statistically significant improvement in SRF and visual acuity in spironolactone treated eyes as compared with the same eyes under observation (p = 0.043, p = 0.047, respectively). There were no complications related to treatment observed.ConclusionsIn naïve eyes with persistent SRF due to central serous chorioretinopathy, spironolactone had a positive effect in the reduction of SRF and recovery of visual acuity.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call